Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs

Executive Summary

Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.


Related Content

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets
AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts